Key Points
- Insider sale: CEO Robert Jr. Spignesi sold 12,840 shares on Feb. 9 at an average price of $3.78 for $48,535.20, trimming his stake to 962,097 shares (a 1.32% decrease) worth roughly $3.64M.
- Stock snapshot: RPID opened at $4.08 with a 52‑week range of $1.86–$4.94, 50‑ and 200‑day moving averages of $3.66 and $3.39, a market cap of about $181M and a negative P/E of -4.04.
- Analyst and institutional backdrop: The consensus rating is "Hold" with an $8.00 target amid mixed analyst calls, and institutions/hedge funds own about 52.6% of the stock with recent buying by Vanguard and others.
Rapid Micro Biosystems, Inc. (NASDAQ:RPID - Get Free Report) COO John Addington Wilson sold 4,610 shares of the stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $3.78, for a total transaction of $17,425.80. Following the completion of the transaction, the chief operating officer directly owned 257,768 shares of the company's stock, valued at approximately $974,363.04. The trade was a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Rapid Micro Biosystems Stock Performance
Rapid Micro Biosystems stock opened at $4.08 on Wednesday. Rapid Micro Biosystems, Inc. has a fifty-two week low of $1.86 and a fifty-two week high of $4.94. The stock's 50 day simple moving average is $3.66 and its two-hundred day simple moving average is $3.39. The company has a debt-to-equity ratio of 0.42, a quick ratio of 2.95 and a current ratio of 4.23. The stock has a market cap of $180.83 million, a price-to-earnings ratio of -4.04 and a beta of 1.38.
Institutional Trading of Rapid Micro Biosystems
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC raised its stake in Rapid Micro Biosystems by 1.6% during the second quarter. Geode Capital Management LLC now owns 204,079 shares of the company's stock valued at $704,000 after buying an additional 3,143 shares during the last quarter. American Century Companies Inc. increased its holdings in shares of Rapid Micro Biosystems by 46.1% during the second quarter. American Century Companies Inc. now owns 16,922 shares of the company's stock valued at $58,000 after acquiring an additional 5,341 shares in the last quarter. XTX Topco Ltd purchased a new position in shares of Rapid Micro Biosystems in the 2nd quarter worth about $144,000. Vanguard Group Inc. boosted its stake in Rapid Micro Biosystems by 6.7% in the 3rd quarter. Vanguard Group Inc. now owns 965,018 shares of the company's stock worth $3,223,000 after purchasing an additional 60,655 shares in the last quarter. Finally, Evernest Financial Advisors LLC grew its position in Rapid Micro Biosystems by 355.1% during the 3rd quarter. Evernest Financial Advisors LLC now owns 200,234 shares of the company's stock valued at $669,000 after purchasing an additional 156,234 shares during the last quarter. Hedge funds and other institutional investors own 52.60% of the company's stock.
Wall Street Analysts Forecast Growth
Several brokerages recently weighed in on RPID. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Rapid Micro Biosystems in a research note on Thursday, January 22nd. Wall Street Zen cut shares of Rapid Micro Biosystems from a "hold" rating to a "sell" rating in a report on Saturday, January 17th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $8.00.
Read Our Latest Research Report on RPID
About Rapid Micro Biosystems
(
Get Free Report)
Rapid Micro Biosystems (NASDAQ: RPID) develops and commercializes automated microbial detection and contamination control solutions for the life sciences industry. Its flagship offering, the Growth Direct® System, leverages digital imaging and proprietary growth indicator plates to identify and count microorganisms more rapidly than traditional culture-based methods. The company's technology platform is designed to streamline quality control workflows in pharmaceutical, biotechnology and vaccine manufacturing settings, helping clients reduce release times and improve operational efficiency.
In addition to the Growth Direct® System, Rapid Micro Biosystems offers an integrated suite of software and consumables that support automated data capture, analysis and reporting.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
